To assess the safety of MG1111 and to evaluate immunological non-inferiority of MG1111 versus comparator
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
814
The subject will receive investigational product or comparator.
The catholic university of Korea, Seoul st. mary's hospital
Banpo-dong, Seoul, South Korea
Proportion of subjects who achieved seroconversion
Time frame: 42 days after vaccination
Geometric mean titer(GMT) measured by the FAMA assay
Time frame: At day 0 and Day 42 post-vaccination
Geometric mean titer(GMT) measured by gpELISA
Time frame: At day 0 and Day 42 post-vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.